{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T11:21:05Z","timestamp":1778498465954,"version":"3.51.4"},"reference-count":26,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2011,9]]},"DOI":"10.1016\/j.intimp.2011.04.015","type":"journal-article","created":{"date-parts":[[2011,5,8]],"date-time":"2011-05-08T03:31:54Z","timestamp":1304825514000},"page":"1319-1326","source":"Crossref","is-referenced-by-count":37,"title":["The selective p38 mitogen-activated protein kinase inhibitor, SB203580, improves renal disease in MRL\/lpr mouse model of systemic lupus"],"prefix":"10.1016","volume":"11","author":[{"given":"Na","family":"Jin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donghai","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kejian","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2011.04.015_bb0005","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/35065000","article-title":"Mammalian MAP kinase signalling cascades","volume":"410","author":"Chang","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2011.04.015_bb0010","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1080\/10408360490427624","article-title":"Biochemical assessment of intracellular signal transduction pathways in eosinophils: implications for pharmacotherapy","volume":"41","author":"Wong","year":"2004","journal-title":"Critical Rev Clin Lab Sci"},{"key":"10.1016\/j.intimp.2011.04.015_bb0015","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.tips.2007.04.008","article-title":"Novel strategies for inhibition of the p38 MAPK pathway","volume":"28","author":"Zhang","year":"2007","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.intimp.2011.04.015_bb0020","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1182\/blood.V91.3.791","article-title":"Beta-chemokine receptor CCR5 signals via the novel tyrosine kinase RAFTK","volume":"91","author":"Ganju","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2011.04.015_bb0025","doi-asserted-by":"crossref","first-page":"921","DOI":"10.2174\/1568026054985902","article-title":"The biology of p38 kinase: a central role in inflammation","volume":"5","author":"Schieven","year":"2005","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.intimp.2011.04.015_bb0030","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1002\/1529-0131(200011)43:11<2501::AID-ANR18>3.0.CO;2-K","article-title":"Activation, differential localization, and regulation of the stress-activated protein kinases, extracellular signal-regulated kinase, c-JUN N-terminal kinase, and p38 mitogen-activated protein kinase, in synovial tissue and cells in rheumatoid arthritis","volume":"43","author":"Schett","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.intimp.2011.04.015_bb0035","doi-asserted-by":"crossref","first-page":"5342","DOI":"10.4049\/jimmunol.168.10.5342","article-title":"p38 mitogen-activated protein kinase is activated and linked to TNF-alpha signaling in inflammatory bowel disease","volume":"168","author":"Waetzig","year":"2002","journal-title":"J Immunol"},{"key":"10.1016\/j.intimp.2011.04.015_bb0040","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1007\/s10875-009-9318-4","article-title":"Activation profile of intracellular mitogen-activated protein kinases in peripheral lymphocytes of patients with systemic lupus erythematosus","volume":"29","author":"Wong","year":"2009","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.intimp.2011.04.015_bb0045","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/01.ASN.0000037402.83851.5F","article-title":"p38 Mitogen-activated protein kinase contributes to autoimmune renal injury in MRL-Faslpr mice","volume":"14","author":"Iwata","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.intimp.2011.04.015_bb0050","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/nrd1177","article-title":"p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases","volume":"2","author":"Kumar","year":"2003","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.intimp.2011.04.015_bb0055","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.2174\/1568026054985939","article-title":"Pathway to the clinic: inhibition of p38 MAP kinase. A review of ten chemotypes selected for development","volume":"5","author":"Goldstein","year":"2005","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.intimp.2011.04.015_bb0060","doi-asserted-by":"crossref","first-page":"867","DOI":"10.2174\/138955706777934982","article-title":"p38 mitogen-activated protein kinase (MAPK) in rheumatoid arthritis","volume":"6","author":"Westra","year":"2006","journal-title":"Mini Rev Med Chem"},{"key":"10.1016\/j.intimp.2011.04.015_bb0065","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1136\/ard.2003.013011","article-title":"Effects of RWJ 67657, a p38 mitogen activated protein kinase (MAPK) inhibitor, on the production of inflammatory mediators by rheumatoid synovial fibroblasts","volume":"63","author":"Westra","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.intimp.2011.04.015_bb0070","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1053\/gast.2002.30770","article-title":"Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn's disease","volume":"122","author":"Hommes","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.intimp.2011.04.015_bb0075","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ddstr.2006.03.003","article-title":"p38 MAP kinase inhibitors: a future therapy for inflammatory diseases","volume":"3","author":"Mayer","year":"2006","journal-title":"Drug Disc Today Ther Strat"},{"key":"10.1016\/j.intimp.2011.04.015_bb0080","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S0163-7258(99)00008-X","article-title":"p38 mitogen-activated protein kinase inhibitors\u2013mechanisms and therapeutic potentials","volume":"82","author":"Lee","year":"1999","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.intimp.2011.04.015_bb0085","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1136\/gut.52.1.144","article-title":"Mitogen activated protein (MAP) kinase signal transduction pathways and novel anti-inflammatory targets","volume":"52","author":"Hommes","year":"2003","journal-title":"Gut"},{"key":"10.1016\/j.intimp.2011.04.015_bb0090","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0022-3565(25)21307-6","article-title":"Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein\/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function","volume":"279","author":"Badger","year":"1996","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.intimp.2011.04.015_bb0095","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1096\/fj.04-1642fje","article-title":"Inhibition of p38 MAP kinase- and RICK\/NF-kappaB-signaling suppresses inflammatory bowel disease","volume":"18","author":"Hollenbach","year":"2004","journal-title":"FASEB J"},{"key":"10.1016\/j.intimp.2011.04.015_bb0100","doi-asserted-by":"crossref","first-page":"7415","DOI":"10.4049\/jimmunol.0804214","article-title":"Modulation of p38 MAPK activity in regulatory T cells after tolerance with anti-DNA Ig peptide in (NZB x NZW)F1 lupus mice","volume":"182","author":"Louren\u00e7o","year":"2009","journal-title":"J Immunol"},{"key":"10.1016\/j.intimp.2011.04.015_bb0105","doi-asserted-by":"crossref","first-page":"4249","DOI":"10.3748\/wjg.v13.i31.4249","article-title":"Inhibition of p38 mitogen-activated protein kinase attenuates experimental autoimmune hepatitis: involvement of nuclear factor kappa B","volume":"13","author":"Ma","year":"2007","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.intimp.2011.04.015_bb0110","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1111\/j.1365-2249.2009.03924.x","article-title":"Activation of AMPK inhibits inflammation in MRL\/lpr mouse mesangial cells","volume":"156","author":"Peairs","year":"2009","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.intimp.2011.04.015_bb0115","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1093\/rheumatology\/ken476","article-title":"Update on immunotherapy for systemic lupus erythematosus\u2013what's hot and what's not!","volume":"48","author":"Karim","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.intimp.2011.04.015_bb0120","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.1002\/art.20576","article-title":"Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study","volume":"50","author":"Aringer","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.intimp.2011.04.015_bb0125","series-title":"Systemic Lupus Erythematosus","author":"Lahita","year":"1999"},{"key":"10.1016\/j.intimp.2011.04.015_bb0130","doi-asserted-by":"crossref","first-page":"5552","DOI":"10.4049\/jimmunol.165.10.5552","article-title":"Molecular mechanisms of B lymphocyte activation by the immune response modifier R-848","volume":"165","author":"Bishop","year":"2000","journal-title":"J Immunol"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576911001883?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576911001883?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T12:31:50Z","timestamp":1741177910000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576911001883"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9]]},"references-count":26,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2011,9]]}},"alternative-id":["S1567576911001883"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2011.04.015","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2011,9]]}}}